The Better Stock for 2021: Moderna or Novavax?

34
15
Favorite

The Better Stock for 2021: Moderna or Novavax?

Motley Fool2021-03-15

So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（15）

TraderKay
·2021-03-15
Comment
Reply
Like
Report
navoyhot
·2021-03-15
moderna seems to be in better shape
Reply
1
Report
go_gym_yo
·2021-03-15
Wow
Reply
Like
Report
车厘子tomato
·2021-03-15
like and comment
Reply
3
Report
Fold Replies
- JFK:
  Liked and commented.
  2021-03-15
  Reply
  Report
- Joeyy:
  Like and comment too
  2021-03-15
  Reply
  Report
tangtkh
·2021-03-15
both good
Reply
Like
Report
sansCervelle
·2021-03-15
thanks!
Reply
3
Report
Timtan85
·2021-03-15
Novavax pls commeent
Reply
5
Report
Fold Replies
- trojan1337:
  sure
  2021-03-15
  Reply
  Report
trojan1337
·2021-03-15
Comment pls!
Reply
5
Report
Fold Replies
- Ivanhojh:
  Thanks!
  2021-03-15
  Reply
  Report
- TheNoobish:
  [财迷]
  2021-03-15
  Reply
  Report
Ivanhojh
·2021-03-15
Comment pls! Thank you.
Reply
2
Report
Fold Replies
- trojan1337:
  ok
  2021-03-15
  Reply
  Report
Ak91
·2021-03-15
Here to milk tiger coins. Pls comment if you are too!
Reply
4
Report
Fold Replies
- Ivanhojh:
  Commented
  2021-03-15
  Reply
  Report
dandan_4896
·2021-03-15
I held a little shares in both :)
Reply
3
Report
Fold Replies
- trader665120:
  ??
  2021-03-15
  Reply
  Report
NicholasL
·2021-03-15
Nice!
Reply
3
Report
JasperSiew
·2021-03-15
Here to earn tiger coins!
Reply
2
Report
Ma_Yi_Long
·2021-03-15
hi pls like and respond to my post. thanks
Reply
1
Report
Fold Replies
- ZacN:
  Comment to my comment please
  2021-03-15
  Reply
  Report
Geniex
·2021-03-15
Please help to like and comment
Reply
4
Report
Fold Replies
- GeniexReplying toMightyPooP:
  thanks
  2021-03-15
  Reply
  Report
- MightyPooP:
  done. comment to my comment pls.
  2021-03-15
  Reply
  Report
- SUPERCHARGER:
  Ok comment back pleaseeee
  2021-03-15
  Reply
  Report
View more 1 comments

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2119963079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-03-15 10:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2119963079","market":"us","top_or_hot":-1,"title":"The Better Stock for 2021: Moderna or Novavax?","media":"Motley Fool","content":"<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","article_id":"2119963079","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","pubTimestamp":1615775939,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"The wisdom of crowds may give us the answer.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"translate_title":"2021年更好的股票：Moderna还是诺瓦瓦克斯医药？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9,"NVAX":0.9},"content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":322186001,"gmtCreate":1615783201003,"gmtModify":1704786425828,"author":{"id":"3574894601222142","authorId":"3574894601222142","name":"TraderKay","avatar":"https://static.tigerbbs.com/9a6982e20765a75972d04e4d50332417","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Comment","listText":"Comment","text":"Comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/322186001","repostId":2119963079,"repostType":4,"repost":{"id":"2119963079","pubTimestamp":1615775939,"share":"https://www.laohu8.com/m/news/2119963079?lang=&edition=full","pubTime":"2021-03-15 10:38","market":"us","language":"en","title":"The Better Stock for 2021: Moderna or Novavax?","url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","media":"Motley Fool","summary":"The wisdom of crowds may give us the answer.","content":"<p>So, we want to find out what the smartest investors are saying about a stock. What's <a href=\"https://laohu8.com/S/AONE\">one</a> of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.</p>\n<p>Here's how it works. Players predict which stocks will beat or lag the <b>S&amp;P 500</b> over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.</p>\n<p>Motley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with <b>Moderna</b> (NASDAQ:MRNA) and <b>Novavax</b> (NASDAQ:NVAX).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2ec578cbf9dca9211feed282d44bc44\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna</h2>\n<p><b>CAPS rating:</b> 3 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.</p>\n<h2>Novavax</h2>\n<p><b>CAPS rating:</b> 2 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.</p>\n<h2>The Foolish bottom line</h2>\n<p>Of the 100 highest-rated stocks on CAPS, only <a href=\"https://laohu8.com/S/AONE.U\">one</a> has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119963079","content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":322180232,"gmtCreate":1615782776926,"gmtModify":1704786420078,"author":{"id":"3549788653484864","authorId":"3549788653484864","name":"navoyhot","avatar":"https://community-static.tradeup.com/news/bfe3e29a700e58ce7b6c853c067b7f3c","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":3,"crmLevelSwitch":1},"htmlText":"moderna seems to be in better shape","listText":"moderna seems to be in better shape","text":"moderna seems to be in better shape","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/322180232","repostId":2119963079,"repostType":2,"repost":{"id":"2119963079","pubTimestamp":1615775939,"share":"https://www.laohu8.com/m/news/2119963079?lang=&edition=full","pubTime":"2021-03-15 10:38","market":"us","language":"en","title":"The Better Stock for 2021: Moderna or Novavax?","url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","media":"Motley Fool","summary":"The wisdom of crowds may give us the answer.","content":"<p>So, we want to find out what the smartest investors are saying about a stock. What's <a href=\"https://laohu8.com/S/AONE\">one</a> of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.</p>\n<p>Here's how it works. Players predict which stocks will beat or lag the <b>S&amp;P 500</b> over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.</p>\n<p>Motley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with <b>Moderna</b> (NASDAQ:MRNA) and <b>Novavax</b> (NASDAQ:NVAX).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2ec578cbf9dca9211feed282d44bc44\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna</h2>\n<p><b>CAPS rating:</b> 3 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.</p>\n<h2>Novavax</h2>\n<p><b>CAPS rating:</b> 2 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.</p>\n<h2>The Foolish bottom line</h2>\n<p>Of the 100 highest-rated stocks on CAPS, only <a href=\"https://laohu8.com/S/AONE.U\">one</a> has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119963079","content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":322110557,"gmtCreate":1615782038579,"gmtModify":1704786405257,"author":{"id":"3576407274098185","authorId":"3576407274098185","name":"go_gym_yo","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/322110557","repostId":2119963079,"repostType":4,"repost":{"id":"2119963079","pubTimestamp":1615775939,"share":"https://www.laohu8.com/m/news/2119963079?lang=&edition=full","pubTime":"2021-03-15 10:38","market":"us","language":"en","title":"The Better Stock for 2021: Moderna or Novavax?","url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","media":"Motley Fool","summary":"The wisdom of crowds may give us the answer.","content":"<p>So, we want to find out what the smartest investors are saying about a stock. What's <a href=\"https://laohu8.com/S/AONE\">one</a> of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.</p>\n<p>Here's how it works. Players predict which stocks will beat or lag the <b>S&amp;P 500</b> over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.</p>\n<p>Motley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with <b>Moderna</b> (NASDAQ:MRNA) and <b>Novavax</b> (NASDAQ:NVAX).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2ec578cbf9dca9211feed282d44bc44\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna</h2>\n<p><b>CAPS rating:</b> 3 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.</p>\n<h2>Novavax</h2>\n<p><b>CAPS rating:</b> 2 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.</p>\n<h2>The Foolish bottom line</h2>\n<p>Of the 100 highest-rated stocks on CAPS, only <a href=\"https://laohu8.com/S/AONE.U\">one</a> has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119963079","content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":322102463,"gmtCreate":1615779371652,"gmtModify":1704786372471,"author":{"id":"3555414544558416","authorId":"3555414544558416","name":"车厘子tomato","avatar":"https://static.tigerbbs.com/a6dbabc7e37fc0d611c52a5194f61d58","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"like and comment","listText":"like and comment","text":"like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/322102463","repostId":2119963079,"repostType":4,"repost":{"id":"2119963079","pubTimestamp":1615775939,"share":"https://www.laohu8.com/m/news/2119963079?lang=&edition=full","pubTime":"2021-03-15 10:38","market":"us","language":"en","title":"The Better Stock for 2021: Moderna or Novavax?","url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","media":"Motley Fool","summary":"The wisdom of crowds may give us the answer.","content":"<p>So, we want to find out what the smartest investors are saying about a stock. What's <a href=\"https://laohu8.com/S/AONE\">one</a> of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.</p>\n<p>Here's how it works. Players predict which stocks will beat or lag the <b>S&amp;P 500</b> over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.</p>\n<p>Motley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with <b>Moderna</b> (NASDAQ:MRNA) and <b>Novavax</b> (NASDAQ:NVAX).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2ec578cbf9dca9211feed282d44bc44\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna</h2>\n<p><b>CAPS rating:</b> 3 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.</p>\n<h2>Novavax</h2>\n<p><b>CAPS rating:</b> 2 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.</p>\n<h2>The Foolish bottom line</h2>\n<p>Of the 100 highest-rated stocks on CAPS, only <a href=\"https://laohu8.com/S/AONE.U\">one</a> has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119963079","content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3796002,"gmtCreate":1615781812952,"gmtModify":1680780389674,"authorId":3567221235003553,"author":{"id":3567221235003553,"authorId":3567221235003553,"name":"JFK","avatar":"https://community-static.tradeup.com/news/a1bbdd2674af7d3373d9670005210691","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":322102463,"type":1,"supId":3795873,"prevId":0,"content":"Liked and commented.","text":"Liked and commented.","html":"Liked and commented."},{"id":3795873,"gmtCreate":1615780421782,"gmtModify":1680780386986,"authorId":3569817266852029,"author":{"id":3569817266852029,"authorId":3569817266852029,"name":"Joeyy","avatar":"https://static.tigerbbs.com/2cb2c8dfcc352a0dfb497e36c25e24c7","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":322102463,"type":1,"supId":0,"prevId":0,"content":"Like and comment too","text":"Like and comment too","html":"Like and comment too"}],"langContent":"EN"},{"id":322376582,"gmtCreate":1615777969446,"gmtModify":1704786358324,"author":{"id":"3574817325947403","authorId":"3574817325947403","name":"tangtkh","avatar":"https://static.tigerbbs.com/d9ad77ea495b2bbbfb9c10734b6f2fb0","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"both good","listText":"both good","text":"both good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/322376582","repostId":2119963079,"repostType":4,"repost":{"id":"2119963079","pubTimestamp":1615775939,"share":"https://www.laohu8.com/m/news/2119963079?lang=&edition=full","pubTime":"2021-03-15 10:38","market":"us","language":"en","title":"The Better Stock for 2021: Moderna or Novavax?","url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","media":"Motley Fool","summary":"The wisdom of crowds may give us the answer.","content":"<p>So, we want to find out what the smartest investors are saying about a stock. What's <a href=\"https://laohu8.com/S/AONE\">one</a> of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.</p>\n<p>Here's how it works. Players predict which stocks will beat or lag the <b>S&amp;P 500</b> over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.</p>\n<p>Motley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with <b>Moderna</b> (NASDAQ:MRNA) and <b>Novavax</b> (NASDAQ:NVAX).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2ec578cbf9dca9211feed282d44bc44\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna</h2>\n<p><b>CAPS rating:</b> 3 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.</p>\n<h2>Novavax</h2>\n<p><b>CAPS rating:</b> 2 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.</p>\n<h2>The Foolish bottom line</h2>\n<p>Of the 100 highest-rated stocks on CAPS, only <a href=\"https://laohu8.com/S/AONE.U\">one</a> has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119963079","content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":322370347,"gmtCreate":1615777503489,"gmtModify":1704786349580,"author":{"id":"3578716728895179","authorId":"3578716728895179","name":"sansCervelle","avatar":"https://community-static.tradeup.com/news/73bb75516984a660b4b1de5c464bb9c1","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"thanks!","listText":"thanks!","text":"thanks!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/322370347","repostId":2119963079,"repostType":4,"repost":{"id":"2119963079","pubTimestamp":1615775939,"share":"https://www.laohu8.com/m/news/2119963079?lang=&edition=full","pubTime":"2021-03-15 10:38","market":"us","language":"en","title":"The Better Stock for 2021: Moderna or Novavax?","url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","media":"Motley Fool","summary":"The wisdom of crowds may give us the answer.","content":"<p>So, we want to find out what the smartest investors are saying about a stock. What's <a href=\"https://laohu8.com/S/AONE\">one</a> of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.</p>\n<p>Here's how it works. Players predict which stocks will beat or lag the <b>S&amp;P 500</b> over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.</p>\n<p>Motley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with <b>Moderna</b> (NASDAQ:MRNA) and <b>Novavax</b> (NASDAQ:NVAX).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2ec578cbf9dca9211feed282d44bc44\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna</h2>\n<p><b>CAPS rating:</b> 3 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.</p>\n<h2>Novavax</h2>\n<p><b>CAPS rating:</b> 2 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.</p>\n<h2>The Foolish bottom line</h2>\n<p>Of the 100 highest-rated stocks on CAPS, only <a href=\"https://laohu8.com/S/AONE.U\">one</a> has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119963079","content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":322346597,"gmtCreate":1615777070119,"gmtModify":1704786343908,"author":{"id":"3573460795152662","authorId":"3573460795152662","name":"Timtan85","avatar":"https://static.tigerbbs.com/5ac241a703d94ceba483abb0655d0b6b","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":2,"crmLevelSwitch":0},"htmlText":"Novavax pls commeent","listText":"Novavax pls commeent","text":"Novavax pls commeent","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/322346597","repostId":2119963079,"repostType":4,"repost":{"id":"2119963079","pubTimestamp":1615775939,"share":"https://www.laohu8.com/m/news/2119963079?lang=&edition=full","pubTime":"2021-03-15 10:38","market":"us","language":"en","title":"The Better Stock for 2021: Moderna or Novavax?","url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","media":"Motley Fool","summary":"The wisdom of crowds may give us the answer.","content":"<p>So, we want to find out what the smartest investors are saying about a stock. What's <a href=\"https://laohu8.com/S/AONE\">one</a> of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.</p>\n<p>Here's how it works. Players predict which stocks will beat or lag the <b>S&amp;P 500</b> over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.</p>\n<p>Motley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with <b>Moderna</b> (NASDAQ:MRNA) and <b>Novavax</b> (NASDAQ:NVAX).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2ec578cbf9dca9211feed282d44bc44\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna</h2>\n<p><b>CAPS rating:</b> 3 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.</p>\n<h2>Novavax</h2>\n<p><b>CAPS rating:</b> 2 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.</p>\n<h2>The Foolish bottom line</h2>\n<p>Of the 100 highest-rated stocks on CAPS, only <a href=\"https://laohu8.com/S/AONE.U\">one</a> has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119963079","content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3795551,"gmtCreate":1615777080854,"gmtModify":1680780381329,"authorId":3574916293171379,"author":{"id":3574916293171379,"authorId":3574916293171379,"name":"trojan1337","avatar":"https://static.tigerbbs.com/943a776c7741ee5cc4d67b3592fbb000","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.65%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":322346597,"type":1,"supId":0,"prevId":0,"content":"sure","text":"sure","html":"sure"}],"langContent":"EN"},{"id":322346291,"gmtCreate":1615777068313,"gmtModify":1704786343100,"author":{"id":"3574916293171379","authorId":"3574916293171379","name":"trojan1337","avatar":"https://static.tigerbbs.com/943a776c7741ee5cc4d67b3592fbb000","vip":1,"hat":"https://static.tigerbbs.com/ae1f49570794979e009a5efdeb6f4789","crmLevel":5,"crmLevelSwitch":1},"htmlText":"Comment pls!","listText":"Comment pls!","text":"Comment pls!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/322346291","repostId":2119963079,"repostType":4,"repost":{"id":"2119963079","pubTimestamp":1615775939,"share":"https://www.laohu8.com/m/news/2119963079?lang=&edition=full","pubTime":"2021-03-15 10:38","market":"us","language":"en","title":"The Better Stock for 2021: Moderna or Novavax?","url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","media":"Motley Fool","summary":"The wisdom of crowds may give us the answer.","content":"<p>So, we want to find out what the smartest investors are saying about a stock. What's <a href=\"https://laohu8.com/S/AONE\">one</a> of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.</p>\n<p>Here's how it works. Players predict which stocks will beat or lag the <b>S&amp;P 500</b> over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.</p>\n<p>Motley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with <b>Moderna</b> (NASDAQ:MRNA) and <b>Novavax</b> (NASDAQ:NVAX).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2ec578cbf9dca9211feed282d44bc44\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna</h2>\n<p><b>CAPS rating:</b> 3 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.</p>\n<h2>Novavax</h2>\n<p><b>CAPS rating:</b> 2 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.</p>\n<h2>The Foolish bottom line</h2>\n<p>Of the 100 highest-rated stocks on CAPS, only <a href=\"https://laohu8.com/S/AONE.U\">one</a> has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119963079","content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3795556,"gmtCreate":1615777122163,"gmtModify":1680780379235,"authorId":3575241823069388,"author":{"id":3575241823069388,"authorId":3575241823069388,"name":"Ivanhojh","avatar":"https://static.tigerbbs.com/a41f0bf4ce9ad13477b3d5ba49c8d025","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":322346291,"type":1,"supId":0,"prevId":0,"content":"Thanks!","text":"Thanks!","html":"Thanks!"},{"id":3795614,"gmtCreate":1615777685475,"gmtModify":1680780376646,"authorId":3573629425643030,"author":{"id":3573629425643030,"authorId":3573629425643030,"name":"TheNoobish","avatar":"https://static.tigerbbs.com/910b578d24b81b2a3a53154a96d972cd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":322346291,"type":1,"supId":3795556,"prevId":0,"content":"[财迷]","text":"[财迷]","html":"[财迷]"}],"langContent":"EN"},{"id":322346307,"gmtCreate":1615777046809,"gmtModify":1704786342777,"author":{"id":"3575241823069388","authorId":"3575241823069388","name":"Ivanhojh","avatar":"https://static.tigerbbs.com/a41f0bf4ce9ad13477b3d5ba49c8d025","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Comment pls! Thank you.&nbsp;","listText":"Comment pls! Thank you.&nbsp;","text":"Comment pls! Thank you.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/322346307","repostId":2119963079,"repostType":4,"repost":{"id":"2119963079","pubTimestamp":1615775939,"share":"https://www.laohu8.com/m/news/2119963079?lang=&edition=full","pubTime":"2021-03-15 10:38","market":"us","language":"en","title":"The Better Stock for 2021: Moderna or Novavax?","url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","media":"Motley Fool","summary":"The wisdom of crowds may give us the answer.","content":"<p>So, we want to find out what the smartest investors are saying about a stock. What's <a href=\"https://laohu8.com/S/AONE\">one</a> of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.</p>\n<p>Here's how it works. Players predict which stocks will beat or lag the <b>S&amp;P 500</b> over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.</p>\n<p>Motley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with <b>Moderna</b> (NASDAQ:MRNA) and <b>Novavax</b> (NASDAQ:NVAX).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2ec578cbf9dca9211feed282d44bc44\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna</h2>\n<p><b>CAPS rating:</b> 3 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.</p>\n<h2>Novavax</h2>\n<p><b>CAPS rating:</b> 2 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.</p>\n<h2>The Foolish bottom line</h2>\n<p>Of the 100 highest-rated stocks on CAPS, only <a href=\"https://laohu8.com/S/AONE.U\">one</a> has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119963079","content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3795554,"gmtCreate":1615777087447,"gmtModify":1680780376238,"authorId":3574916293171379,"author":{"id":3574916293171379,"authorId":3574916293171379,"name":"trojan1337","avatar":"https://static.tigerbbs.com/943a776c7741ee5cc4d67b3592fbb000","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.65%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":322346307,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"EN"},{"id":322349988,"gmtCreate":1615776705044,"gmtModify":1704786336461,"author":{"id":"3573276404004652","authorId":"3573276404004652","name":"Ak91","avatar":"https://static.tigerbbs.com/0578c6f4e6345562f2d636b87cc2b9fd","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Here to milk tiger coins. Pls comment if you are too!","listText":"Here to milk tiger coins. Pls comment if you are too!","text":"Here to milk tiger coins. Pls comment if you are too!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/322349988","repostId":2119963079,"repostType":4,"repost":{"id":"2119963079","pubTimestamp":1615775939,"share":"https://www.laohu8.com/m/news/2119963079?lang=&edition=full","pubTime":"2021-03-15 10:38","market":"us","language":"en","title":"The Better Stock for 2021: Moderna or Novavax?","url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","media":"Motley Fool","summary":"The wisdom of crowds may give us the answer.","content":"<p>So, we want to find out what the smartest investors are saying about a stock. What's <a href=\"https://laohu8.com/S/AONE\">one</a> of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.</p>\n<p>Here's how it works. Players predict which stocks will beat or lag the <b>S&amp;P 500</b> over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.</p>\n<p>Motley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with <b>Moderna</b> (NASDAQ:MRNA) and <b>Novavax</b> (NASDAQ:NVAX).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2ec578cbf9dca9211feed282d44bc44\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna</h2>\n<p><b>CAPS rating:</b> 3 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.</p>\n<h2>Novavax</h2>\n<p><b>CAPS rating:</b> 2 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.</p>\n<h2>The Foolish bottom line</h2>\n<p>Of the 100 highest-rated stocks on CAPS, only <a href=\"https://laohu8.com/S/AONE.U\">one</a> has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119963079","content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3795552,"gmtCreate":1615777082422,"gmtModify":1680780378686,"authorId":3575241823069388,"author":{"id":3575241823069388,"authorId":3575241823069388,"name":"Ivanhojh","avatar":"https://static.tigerbbs.com/a41f0bf4ce9ad13477b3d5ba49c8d025","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":322349988,"type":1,"supId":0,"prevId":0,"content":"Commented","text":"Commented","html":"Commented"}],"langContent":"EN"},{"id":322340578,"gmtCreate":1615776680594,"gmtModify":1704786336782,"author":{"id":"3576232257279797","authorId":"3576232257279797","name":"dandan_4896","avatar":"https://static.tigerbbs.com/d8b00e27a4dd6f248e38c3d78f21f188","vip":1,"crmLevel":2,"crmLevelSwitch":1},"htmlText":"I held a little shares in both :)","listText":"I held a little shares in both :)","text":"I held a little shares in both :)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/322340578","repostId":2119963079,"repostType":4,"repost":{"id":"2119963079","pubTimestamp":1615775939,"share":"https://www.laohu8.com/m/news/2119963079?lang=&edition=full","pubTime":"2021-03-15 10:38","market":"us","language":"en","title":"The Better Stock for 2021: Moderna or Novavax?","url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","media":"Motley Fool","summary":"The wisdom of crowds may give us the answer.","content":"<p>So, we want to find out what the smartest investors are saying about a stock. What's <a href=\"https://laohu8.com/S/AONE\">one</a> of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.</p>\n<p>Here's how it works. Players predict which stocks will beat or lag the <b>S&amp;P 500</b> over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.</p>\n<p>Motley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with <b>Moderna</b> (NASDAQ:MRNA) and <b>Novavax</b> (NASDAQ:NVAX).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2ec578cbf9dca9211feed282d44bc44\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna</h2>\n<p><b>CAPS rating:</b> 3 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.</p>\n<h2>Novavax</h2>\n<p><b>CAPS rating:</b> 2 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.</p>\n<h2>The Foolish bottom line</h2>\n<p>Of the 100 highest-rated stocks on CAPS, only <a href=\"https://laohu8.com/S/AONE.U\">one</a> has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119963079","content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3795925,"gmtCreate":1615780876721,"gmtModify":1680780385714,"authorId":3574752370638367,"author":{"id":3574752370638367,"authorId":3574752370638367,"name":"trader665120","avatar":"https://static.tigerbbs.com/c237827872d4863e1dc615224be0fa5e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":322340578,"type":1,"supId":0,"prevId":0,"content":"??","text":"??","html":"??"}],"langContent":"EN"},{"id":322357533,"gmtCreate":1615776560122,"gmtModify":1704786334953,"author":{"id":"3573473078665709","authorId":"3573473078665709","name":"NicholasL","avatar":"https://static.tigerbbs.com/4f3f4edbf993855f3efeac6e212f55ec","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/322357533","repostId":2119963079,"repostType":4,"repost":{"id":"2119963079","pubTimestamp":1615775939,"share":"https://www.laohu8.com/m/news/2119963079?lang=&edition=full","pubTime":"2021-03-15 10:38","market":"us","language":"en","title":"The Better Stock for 2021: Moderna or Novavax?","url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","media":"Motley Fool","summary":"The wisdom of crowds may give us the answer.","content":"<p>So, we want to find out what the smartest investors are saying about a stock. What's <a href=\"https://laohu8.com/S/AONE\">one</a> of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.</p>\n<p>Here's how it works. Players predict which stocks will beat or lag the <b>S&amp;P 500</b> over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.</p>\n<p>Motley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with <b>Moderna</b> (NASDAQ:MRNA) and <b>Novavax</b> (NASDAQ:NVAX).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2ec578cbf9dca9211feed282d44bc44\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna</h2>\n<p><b>CAPS rating:</b> 3 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.</p>\n<h2>Novavax</h2>\n<p><b>CAPS rating:</b> 2 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.</p>\n<h2>The Foolish bottom line</h2>\n<p>Of the 100 highest-rated stocks on CAPS, only <a href=\"https://laohu8.com/S/AONE.U\">one</a> has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119963079","content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":322354579,"gmtCreate":1615776473591,"gmtModify":1704786332849,"author":{"id":"3577217753530730","authorId":"3577217753530730","name":"JasperSiew","avatar":"https://static.tigerbbs.com/83f722cf0862155d9c02263c3985c2ee","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Here to earn tiger coins!","listText":"Here to earn tiger coins!","text":"Here to earn tiger coins!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/322354579","repostId":2119963079,"repostType":4,"repost":{"id":"2119963079","pubTimestamp":1615775939,"share":"https://www.laohu8.com/m/news/2119963079?lang=&edition=full","pubTime":"2021-03-15 10:38","market":"us","language":"en","title":"The Better Stock for 2021: Moderna or Novavax?","url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","media":"Motley Fool","summary":"The wisdom of crowds may give us the answer.","content":"<p>So, we want to find out what the smartest investors are saying about a stock. What's <a href=\"https://laohu8.com/S/AONE\">one</a> of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.</p>\n<p>Here's how it works. Players predict which stocks will beat or lag the <b>S&amp;P 500</b> over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.</p>\n<p>Motley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with <b>Moderna</b> (NASDAQ:MRNA) and <b>Novavax</b> (NASDAQ:NVAX).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2ec578cbf9dca9211feed282d44bc44\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna</h2>\n<p><b>CAPS rating:</b> 3 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.</p>\n<h2>Novavax</h2>\n<p><b>CAPS rating:</b> 2 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.</p>\n<h2>The Foolish bottom line</h2>\n<p>Of the 100 highest-rated stocks on CAPS, only <a href=\"https://laohu8.com/S/AONE.U\">one</a> has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119963079","content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":322352239,"gmtCreate":1615776282421,"gmtModify":1704786331235,"author":{"id":"3557722898030015","authorId":"3557722898030015","name":"Ma_Yi_Long","avatar":"https://static.tigerbbs.com/87e91b153216a6f84a5a4ac58894a42e","vip":1,"crmLevel":5,"crmLevelSwitch":1},"htmlText":"hi pls like and respond to my post. thanks","listText":"hi pls like and respond to my post. thanks","text":"hi pls like and respond to my post. thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/322352239","repostId":2119963079,"repostType":4,"repost":{"id":"2119963079","pubTimestamp":1615775939,"share":"https://www.laohu8.com/m/news/2119963079?lang=&edition=full","pubTime":"2021-03-15 10:38","market":"us","language":"en","title":"The Better Stock for 2021: Moderna or Novavax?","url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","media":"Motley Fool","summary":"The wisdom of crowds may give us the answer.","content":"<p>So, we want to find out what the smartest investors are saying about a stock. What's <a href=\"https://laohu8.com/S/AONE\">one</a> of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.</p>\n<p>Here's how it works. Players predict which stocks will beat or lag the <b>S&amp;P 500</b> over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.</p>\n<p>Motley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with <b>Moderna</b> (NASDAQ:MRNA) and <b>Novavax</b> (NASDAQ:NVAX).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2ec578cbf9dca9211feed282d44bc44\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna</h2>\n<p><b>CAPS rating:</b> 3 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.</p>\n<h2>Novavax</h2>\n<p><b>CAPS rating:</b> 2 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.</p>\n<h2>The Foolish bottom line</h2>\n<p>Of the 100 highest-rated stocks on CAPS, only <a href=\"https://laohu8.com/S/AONE.U\">one</a> has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119963079","content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3795505,"gmtCreate":1615776702099,"gmtModify":1680780374800,"authorId":3577220211671569,"author":{"id":3577220211671569,"authorId":3577220211671569,"name":"ZacN","avatar":"https://static.tigerbbs.com/4b39e21f419b5bf9c135c152e2e2b227","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.11.22","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":322352239,"type":1,"supId":0,"prevId":0,"content":"Comment to my comment please","text":"Comment to my comment please","html":"Comment to my comment please"}],"langContent":"EN"},{"id":322358332,"gmtCreate":1615776027026,"gmtModify":1704786328163,"author":{"id":"3574943393887740","authorId":"3574943393887740","name":"Geniex","avatar":"https://static.tigerbbs.com/581664640a374b5a1a5c0cc84f9d53f4","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0},"htmlText":"Please help to like and comment","listText":"Please help to like and comment","text":"Please help to like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/322358332","repostId":2119963079,"repostType":4,"repost":{"id":"2119963079","pubTimestamp":1615775939,"share":"https://www.laohu8.com/m/news/2119963079?lang=&edition=full","pubTime":"2021-03-15 10:38","market":"us","language":"en","title":"The Better Stock for 2021: Moderna or Novavax?","url":"https://stock-news.laohu8.com/highlight/detail?id=2119963079","media":"Motley Fool","summary":"The wisdom of crowds may give us the answer.","content":"<p>So, we want to find out what the smartest investors are saying about a stock. What's <a href=\"https://laohu8.com/S/AONE\">one</a> of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.</p>\n<p>Here's how it works. Players predict which stocks will beat or lag the <b>S&amp;P 500</b> over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.</p>\n<p>Motley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with <b>Moderna</b> (NASDAQ:MRNA) and <b>Novavax</b> (NASDAQ:NVAX).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e2ec578cbf9dca9211feed282d44bc44\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Moderna</h2>\n<p><b>CAPS rating:</b> 3 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.</p>\n<h2>Novavax</h2>\n<p><b>CAPS rating:</b> 2 out of 5 stars</p>\n<p><b>What investors might be noticing:</b> Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.</p>\n<h2>The Foolish bottom line</h2>\n<p>Of the 100 highest-rated stocks on CAPS, only <a href=\"https://laohu8.com/S/AONE.U\">one</a> has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Better Stock for 2021: Moderna or Novavax?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Better Stock for 2021: Moderna or Novavax?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 10:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/03/14/the-better-stock-for-2021-moderna-or-novavax/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119963079","content_text":"So, we want to find out what the smartest investors are saying about a stock. What's one of the best ways of doing that? By playing a game. But not just any game. I'm talking about Motley Fool CAPS. It's a stock-picking game that uses the wisdom of crowds to find great investments.\nHere's how it works. Players predict which stocks will beat or lag the S&P 500 over a particular time frame. CAPS then gives players ratings based on their performance versus other players. And CAPS rates stocks according to the number of players who say they'll outperform. A key point: The game weighs the opinions of highly rated players more heavily.\nMotley Fool CAPS is fun, but more importantly, it can help you use the wisdom of crowds as you build or expand your portfolio. Let's give it a try with Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX).\nImage source: Getty Images.\nModerna\nCAPS rating: 3 out of 5 stars\nWhat investors might be noticing: They probably like the fact that Moderna has started generating revenue from its coronavirus vaccine. And the company expects $18.4 billion in product sales this year, according to advance purchase agreements so far. What's holding this stock back from a higher rating? Moderna shares climbed more than 400% last year; some might worry that the good news is priced in. Another concern is the vaccine's performance against new variants. Moderna says its vaccine can handle the new strains, but those tests were in vitro, not in living subjects.\nNovavax\nCAPS rating: 2 out of 5 stars\nWhat investors might be noticing: Novavax has reported strong data from a phase 3 trial of its coronavirus vaccine candidate and has built an extensive manufacturing network. The biotech also has another close-to-market candidate: a potential flu vaccine. What's holding Novavax back from a better score? The stock already surged more than 2,700% last year; some worry further gains may be limited. Another concern is competition. Three other coronavirus vaccines have already entered the U.S. market. It may be difficult for Novavax to carve out a share.\nThe Foolish bottom line\nOf the 100 highest-rated stocks on CAPS, only one has posted a negative performance over the past year. And of the six CAPS stocks that have surged more than 1,000% over the past year, four have three stars and two have five stars. So, the highest-rated stocks generally outperform over time. If we use CAPS wisdom, it looks like Moderna may be the better stock for 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3795867,"gmtCreate":1615780391538,"gmtModify":1680780389417,"authorId":3574943393887740,"author":{"id":3574943393887740,"authorId":3574943393887740,"name":"Geniex","avatar":"https://static.tigerbbs.com/581664640a374b5a1a5c0cc84f9d53f4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3575163551534398,"repliedAuthor":{"id":3575163551534398,"authorId":3575163551534398,"name":"MightyPooP","avatar":"https://static.tigerbbs.com/aec66d00ca2b1f2b75412008d93edd14","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"objectId":322358332,"type":1,"supId":3795425,"prevId":3795444,"content":"<u>thanks</u>","text":"<u>thanks</u>","html":"<u>thanks</u>"},{"id":3795444,"gmtCreate":1615776212065,"gmtModify":1680780381630,"authorId":3575163551534398,"author":{"id":3575163551534398,"authorId":3575163551534398,"name":"MightyPooP","avatar":"https://static.tigerbbs.com/aec66d00ca2b1f2b75412008d93edd14","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":322358332,"type":1,"supId":3795425,"prevId":0,"content":"done. comment to my comment pls.","text":"done. comment to my comment pls.","html":"done. comment to my comment pls."},{"id":3795425,"gmtCreate":1615776088098,"gmtModify":1680780378073,"authorId":3561239881014940,"author":{"id":3561239881014940,"authorId":3561239881014940,"name":"SUPERCHARGER","avatar":"https://static.tigerbbs.com/1d8977ccd4cef3718d77de1198ec99b1","vip":1,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":322358332,"type":1,"supId":0,"prevId":0,"content":"Ok comment back pleaseeee","text":"Ok comment back pleaseeee","html":"Ok comment back pleaseeee"},{"id":3795461,"gmtCreate":1615776307138,"gmtModify":1680780377272,"authorId":3557722898030015,"author":{"id":3557722898030015,"authorId":3557722898030015,"name":"Ma_Yi_Long","avatar":"https://static.tigerbbs.com/87e91b153216a6f84a5a4ac58894a42e","vip":1,"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":322358332,"type":1,"supId":0,"prevId":0,"content":"sure","text":"sure","html":"sure"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":34,"commentSize":15,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}